4
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Methylprednisolone versus Metoclopramide as Antiemetic Treatment in Patients Receiving Adjuvant Cyclophosphamide, Methotrexate, 5-Fluorouracil (CMF) Chemotherapy: A randomized crossover blind study.

, , , , , , & show all
Pages 365-368 | Published online: 14 Jul 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

E. Campora, E. Baldini, A. Rubagotti, S. Chiara, P. Bruzzi, M.R. Sertoli & R. Rosso. (1990) Double-Blind Randomized Trial of Lorazepam versus Placebo with Methylprednisolone for Control of Emesis Due to Non-Cisplatin Containing Chemotherapy. Journal of Chemotherapy 2:5, pages 336-339.
Read now

Articles from other publishers (5)

S.M. Grunberg. (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Annals of Oncology 18:2, pages 233-240.
Crossref
Jens M. Stieler, Peter Reichardt, Hanno Riess & Helmut Oettle. (2003) Treatment Options for Chemotherapy-Induced Nausea and Vomiting. American Journal of Cancer 2:1, pages 15-26.
Crossref
Richard J. GrallaDavid OsobaMark G. KrisPeter KirkbridePaul J. HeskethLawrence W. ChinneryRebecca Clark-SnowDavid P. GillSusan GroshenSteven GrunbergJames M. KoellerGary R. MorrowEdith A. PerezJeffrey H. SilberDavid G. Pfister. (1999) Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. Journal of Clinical Oncology 17:9, pages 2971-2971.
Crossref
Miguel Martin & Eduardo Díaz-Rubio. 1996. Antiemetics in the Supportive Care of Cancer Patients. Antiemetics in the Supportive Care of Cancer Patients 61 72 .
Eliahu Gez, Nurith Strauss, Nehama Vitzhaki, Yaakov Cass & David Zvi Edelmann. (1992) Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. Cancer Chemotherapy and Pharmacology 30:3, pages 229-232.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.